Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PPP5C | P53041 | 2/20 | 0.38 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471423 | 0.93 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1ALDH1A1HRH3POLB | |
| SCHEMBL2856149 | 0.92 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1ACHEHRH3 | |
| SCHEMBL12881320 | 0.86 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1ALDH1A1ACHEHRH3 | |
| SCHEMBL27717811 | 0.86 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1ALDH1A1ACHEHRH3 | |
| SCHEMBL4461999 | 0.85 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1ALDH1A1ACHEHTT | |
| SCHEMBL2553841 | 0.85 | HRH3 (0.44) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL65329 | 0.85 | HRH3 (0.47) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL4072905 | 0.84 | CYP1A2 (0.61) | L3MBTL3L3MBTL1ALDH1A1ACHEHRH3 | |
| SCHEMBL2550326 | 0.83 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1ALDH1A1HRH3KCNH2 | |
| SCHEMBL23269622 | 0.82 | CYP1A2 (0.59) | L3MBTL3L3MBTL1ALDH1A1ACHEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | claimed |
| EP-3233071-B1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS LLC (US) | 2019-09-18 | — | — | EP | claimed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | claimed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | claimed |
| CN-101952276-B | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO.KG (DE) | 2014-10-22 | — | — | CN | claimed |
| CN-107466232-B | Methods of treating or preventing RAS-mediated diseases | ADT制药有限责任公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-112047909-A | Indenyl compound, pharmaceutical composition and medical application thereof | ADT制药有限责任公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-107531615-B | Indenyl compound, pharmaceutical composition and medical application thereof | ADT制药有限责任公司 | 2020-09-04 | — | — | CN | disclosed |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2017-02-23 | — | — | US | disclosed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2015-06-11 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | AbbVie Deutschland GmbH & Co. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| CN-1906166-A | Novel pyridine derivative and pyrimidine derivative (1) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1667993-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | Abbott GmbH & Co. KG (DE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005030755-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | L3MBTL3 1125/4885L3MBTL1 1054/4885ALDH1A1 557/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | L3MBTL3 1402/4885L3MBTL1 1338/4885ALDH1A1 930/4885 |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | OXTR, AVPR2, AVPR1A | L3MBTL3 1593/4885L3MBTL1 1148/4885ALDH1A1 920/4885 |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | L3MBTL3 1922/4885L3MBTL1 2942/4885ALDH1A1 2411/4885 |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | L3MBTL3 1720/4885L3MBTL1 1325/4885ALDH1A1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.